Summer is just around the corner and there was real optimism in the air this week as Optimum’s clients looked forward to 2024, with the conference season about to start. Medicxi Announces £40m investment in D3 Bio Medicxi, a leading European life sciences investment firm, on Monday announced an investment of $40 million in D3 […]
It was a short week after the Easter break but there was plenty of positive news from Optimum’s clients with summer just around the corner. Novo Holdings Asia Investment on the up Novo Holdings’ Asia Investments team on Wednesday published its annual review – a year of developing and building for long-term results. During 2023, […]
Congratulations to our clients AstronauTx and STORM Therapeutics, which were recognised at the inaugural One Nucleus Awards in London in March. AstronauTx scooped the Best Performing Primary R&D Company of the Year Award, while STORM won the One Nucleus Boston Bootcamp competition aimed at getting companies “US-ready”. AstronauTx beat off strong competition to win the […]
The nights are getting shorter and the green shoots of spring are emerging – and it’s an exciting time for Optimum Strategic Communications as it launches Optimum TV! Our associate director and former national newspaper journalist Stephen Adams will be presenting regular YouTube episodes showcasing our clients’ amazing work. Heidelberg grabs orphan designation Heidelberg […]
Novo Holdings leads Clasp Therapeutics’ $150m fundraiser Novo Holdings co-led Clasp Therapeutics’ $150 million fundraiser to develop precision immune-oncology using next-generation T-cell engagers. Clasp is leveraging advances made by its scientific founders at Johns Hopkins University, including leading cancer geneticist and HHMI investigator Bert Vogelstein, M.D., and immuno-oncology pioneer Drew Pardoll, M.D., Ph.D., who have […]
